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Abstarct  
The introduction of antimicrobial agents was a breakthrough health intervention that helped save millions of 
lives around the world and that provided a sense of control on the part of clinicians over host pathogen 
interactions. Despite the concrete advances in prevention and treatment of infectious diseases, there has been a 
parallel surge in resistance to antimicrobials that is seriously compromising the gains made over the past century. 
There are many other factors which contribute to the rising incidence of resistance in human pathogens.  These 
factors include liberal availability of antimicrobials in some countries and societal factors such as the increasing 
number of immunosuppressed individuals, unnecessary antimicrobial use caused by patient demands for 
antimicrobial treatment of viral infections, the changing population age structure, and an increase in institutional 
care environments such as day care centers, nursing homes and hospitals. In animals, frequent and overdose use 
of antibiotics as a growth promoters is the dominant cause of antimicrobial resistance. The impact of drug 
resistance has been causing a severe effect in the control and prevention of diseases in both human beings and 
livestock. Acknowledging the underlying mechanisms such as inappropriate use of antibiotics in humans and the 
agricultural applications of antibiotics for growth promotion and prophylaxis is a first and essential step to 
contain global antimicrobial resistance. However, it is also critical to consider in parallel the broad social, 
economic and political drivers and ethical significance of antimicrobial promotion in developing countries. 
Moreover, these socio-ethical factors constitute tangible targets against which public policy interventions can be 
developed to remedy growing concerns over the spread of antimicrobial resistance. 
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1. INTRODUCTION 
Antimicrobials are used to treat infections that can be caused by different microorganisms, including bacteria, 
viruses, parasites and fungi. In the vast majority of cases where antimicrobials are used, the microorganisms find 
a way to evade or resist the antimicrobial agent. Resistance occurs wherever antimicrobials are used in the 
community, on a farm, and in healthcare centers. The introduction of penicillin, in the early 1940s, was 
perceived as marking the end of infectious diseases (Abraham and Chain, 1940). However, the emergences of 
resistant strains were reported just a few years after its use. Since then, resistant clones to various classes of 
antibiotics have been found to spread worldwide (Manges et al., 2001). In some areas, more than 90% resistance 
has been reported to commonly used antibiotics such as penicillin, ampicillin, co-trimoxazole and gentamicin 
(Mshana et al., 2009).  
The overuse of antibiotics in human and animals has contributed to the emergence of resistant clones 
(Aarestrup and Wegener, 1999; Barton and Wilkins, 2001). It is a fact that the availability of antimicrobials 
and their proper use have reduced morbidity and mortality due to infectious disease. In developed countries, 
the use of antibiotics is strictly controlled, which is not the case in developing countries. The treatment of 
bacterial infections in developing countries like Africa is largely empirical and in most instances, there are no 
laboratory results to guide therapy. Moreover, there are no data on common bacterial isolates and their 
susceptibility patterns from larger surveillance studies aimed at developing tools for therapeutic guidance. 
Developing countries bear 95% of the global infectious diseases burden and rely on empirical antimicrobial 
treatment to counteract these diseases (Hart and Kariuk, 1998). This has resulted in many infectious diseases, 
once easily curable, to become untreatable (Vlieghe, 2008; WHO, 2011). 
Methicillin resistant S. aureus, Penicillin resistant Streptococcus pneumoniae and multi-resistant 
Mycobacterium tuberculosis are among the few antimicrobial-resistant microbes that pose serious ongoing 
challenges to biomedicine and public health. While substantial progress has been made in discerning the 
underlying biological, genetic and environmental causes of the emergence of antimicrobial resistance, there has 
been much less attention to important social factors such as socio-economic disparities and the impact of drug 
development and delivery strategies in both developed and developing countries. The inappropriate use of 
antimicrobial and the underlying mechanisms of antimicrobial resistance have broad social and ethical 
significance that transcends individual patients or specific communities who suffer from treatment failures 
(oliver et al., 2010).  
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Hence, the objective of this seminar paper is:  
 To provide an insight on the general implication of drug resistant bacteria in developing countries related to 
control of infectious diseases. 
 
2. DRUG RESISTANT MICROORGANISMS 
2.1. Drug resistant bacteria  
Staphylococcus aureus (informally known as "Staph aureus" or a "Staph infection") is one of the major resistant 
pathogens. Found on the mucous membranes and the human and animals skin of around a third of the population.  
It is extremely adaptable to antimicrobial pressure. It was one of the earlier bacteria in which penicillin 
resistance was found in 1947 just four years after the drug started being mass-produced. Methicillin was then the 
antimicrobial of choice, but has since been replaced by Oxacillin due to significant kidney toxicity. Methicillin-
resistant Staphylococcus aureus (MRSA) was first detected in Britain in 1961, and is now "quite common" in 
hospitals. MRSA was responsible for 37% of fatal cases of sepsis in the UK in 1999, up from 4% in 1991. Half 
of all S. aureus infections in the U.S are resistant to Penicillin, Methicillin, Tetracycline and Erythromycin 
(Bozdogan et al., 2003). 
Streptococcus pyogenes (Group A Streptococcus: GAS) infections can usually be treated with, many 
different antimicrobials. Early treatment may reduce the risk of death from invasive group A streptococcal 
disease. However, even the best medical care does not prevent death in every case. For those with very severe 
illness, supportive care in an intensive-care unit may be needed. For persons with necrotizing fasciitis, surgery 
often is needed to remove damaged tissue. Strains of S. pyogenes resistant to macrolide antimicrobial have 
emerged; however, all strains remain uniformly susceptible to penicillin (Albrich et al., 2004). Resistance of 
Streptococcus pneumoniae to Penicillin and other beta-lactams is increasing worldwide. S. pneumoniae is 
responsible for pneumonia, bacteremia, otitis media, meningitis, sinusitis, peritonitis and arthritis (Albrich et 
al., 2004). 
Pseudomonas aeruginosa is a highly prevalent opportunistic pathogen. One of the most worrisome 
characteristics of P. aeruginosa is its low antimicrobial susceptibility, which is attributable to a concerted 
action of multidrug efflux pumps with chromosomally encoded antimicrobial resistance genes and the low 
permeability of the bacterial cellular envelopes (Poole, 2004). Clostridium difficile is a nosocomial pathogen 
that causes diarrheal disease in hospitals worldwide (Gerding et al., 1995; McDonald, 2005). C. difficile colitis 
is most strongly associated with Fluoroquinolones, Cephalosporins, Carbapenems, and Clindamycin (Gifford 
and Kirkland, 2006; Baxter et al., 2008).  
Some research suggests the overuse of antimicrobial in the raising of livestock is contributing to 
outbreaks of bacterial infections such as C. difficile. Antimicrobials, especially those with a broad activity 
spectrum (such as clindamycin) disrupt normal intestinal flora. This can lead to an overgrowth of C. difficile, 
which flourishes under these conditions. Pseudomembranous colitis can follow, creating generalized 
inflammation of the colon and the development of "pseudo membrane", a viscous collection of inflammatory 
cells, fibrin, and necrotic cells. Infection with Escherichia coli and Salmonella can result from the consumption 
of contaminated food and water. Both of these bacteria are well known for causing nosocomial (hospital-linked) 
infections, and often, these strains found in hospitals are antibiotic resistant due to adaptations to wide spread 
antibiotic use (Davies and Davies, 2010).  
Klebsiella pneumonia carbapenemase (KPC)-producing bacteria are a group of emerging highly drug-
resistant Gram-negative bacilli causing infections associated with significant morbidity and mortality whose 
incidence is rapidly increasing in a variety of clinical settings around the world. Klebsiella pneumoniae 
includes numerous mechanisms for antimicrobial resistance, many of which are located on highly mobile 
genetic elements (Hudson et al., 2014). Carbapenem antimicrobials are generally not effective against KPC-
producing organisms (Arnold et al., 2011). 
Tuberculosis is increasing across the globe, especially in developing countries, over the past few years. 
TB resistant to antibiotics is called Multidrug Resistant TB (MDR TB). Globally, MDR TB causes 150,000 
deaths annually (Edward et al., 2013). The rise of the HIV/AIDS epidemic has contributed to this (LoBue, 
2009). 
TB was considered one of the most prevalent diseases, and did not have a cure until the discovery of 
Streptomycin by Selman Waksman in 1943 (Herzog, 1998). However, the bacteria soon developed resistance. 
Since then, drugs such as Isoniazid and Rifampin have been used. M. tuberculosis develops resistance to drugs 
by spontaneous mutations in its genomes. Resistance to one drug is common, and this is why treatment is 
usually done with more than one drug. Extensively Drug-Resistant TB (XDR TB) is TB that is also resistant to 
the second line of drugs (LoBue, 2009; Gao et al., 2010). 
Neisseria gonorrhoeae is a sexually transmitted pathogen that can cause pelvic pain, pain on urination, 
penile and vaginal discharge, as well as systemic symptoms. The bacteria were first identified in 1879 (Ligon 
and Lee, 2005). In the 1940s effective treatment with Penicillin became available, but by the 1970s resistant 
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strains predominated.  
 
2.2. Mechanisms of antimicrobial resistance  
The emergence of resistance in microbes can be precipitated most obviously by overuse of antimicrobials. 
Inappropriate antimicrobial use can easily develop as a downstream consequence of excessive drug promotion 
activities invulnerable global populations who maybe devoid of in formation channels to make informed 
decisions on benefits and risks of antimicrobials .Hence, it is not surprising that the use and prescription of 
antimicrobials, which escalated significantly until the mid-1990s, was immediately followed by an increase in 
antimicrobial resistance worldwide (McCaig et al.,1998).  
The different types of drug resistance mechanisms used by various bacterial species are mentioned as follows: 
2.2.1. Mutational alteration of the target protein 
Man-made compounds, such as Fluoroquinolones, are unlikely to become inactivated by the enzymatic 
mechanisms described below. However, bacteria can still become resistant through mutations that make the 
target protein less susceptible to the agent. Fluorquinolone resistance is mainly (but not exclusively) due to 
mutations in the target enzymes, DNA topoisomerases (Hooper, 2000). 
Another example of resistance attributable to target modification is that conferred by the erm gene, 
which is usually plasmid coded and produces the methylation of adenine at position 2058 of the 50S rRNA, 
causing resistance to macrolides (Erythromycin and many others), Lincosamide, and Streptogramin (Weisblum, 
1995). Sulfa drugs (synthetic competitors of p-aminobenzoic acids that inhibit dihydropteroatesynthetase and 
trimethoprim, a synthetic inhibitor of dihydrofolatereductase) have been used in combination. They select for 
drug-resistant mutants of the respective enzymes. In this case, the high-level production of drug-resistant target 
enzymes from plasmids can make the bacteria resistant, and the resistant genes have spread widely on plasmids 
(Huovinen et al., 1995). 
2.2.2 . Enzymatic inactivation of the drug 
This is a common resistance mechanism for antibiotics of natural origin, such as aminoglycosides (Kanamycin, 
Tobramycin, and Amikacin), which are inactivated by enzymatic phosphorylation 
byaminoglycosidephosphoryltransferase (APH), acetylation by Aminoglycoside acetyltransferase (AAC), or 
adenylation (by aminoglycoside adenyltransferase or nucleotidyl transferase), and β-lactams (Penicillins, 
Cephalosporins, and Carbapenems such as Imipenem), which are inactivated by enzymatic hydrolysis by β-
lactamases, usually in the periplasm. Genes coding for these inactivating enzymes can easily produce resistance 
as additional genetic components on plasmids (Hooper, 2000). 
2.2.3. Acquisition of genes for less susceptible target proteins from other species 
Sequencing of the genes coding for the targets of Penicillin, DD-transpeptidase or penicillin-binding proteins 
(PBPs), revealed that penicillin resistance among Streptococcus pneumoniae was due to the production of 
mosaic proteins, parts of which came from other organisms. We note that S. pneumoniae is an organism capable 
of natural transformation and may import foreign DNA. Interestingly, a similar mechanism of penicillin 
resistance was also found in another organism capable of natural transformation. An extreme case of this 
scenario is the generation of MRSA. MRSA strains contain a new methicillin-resistant PBP, called PBP-2A or 2′, 
whose expression is often induced by methicillin and other β-lactams. The gene for this new PBP is located in a 
large (30–60-kb) segment of DNA, which apparently came from an organism other than S. aureus and also 
contains other antibiotic resistance genes. S. aureus is not naturally transformable, and it is unclear how this 
horizontal transfer of a large DNA segment occurred (Kuroda et al., 2001; De-Lencastre et al., 2007). 
2.2.4.  Bypassing of the target 
VanA-type resistance, which is a high level of resistance to Vancomycin and Teicoplanin, is mediated by 
transposon Tn1546, which encodes proteins involved in transposition, regulation of resistance expression, 
synthesis of modified peptidoglycan precursors ending in d-alanine-d-lactate (d-Ala-d-Lac), and elimination of 
normal precursors ending in d-Ala-d-Ala (Arthur et al., 1996). Synthesis of pentadepsipeptide precursors is 
responsible for diminished binding affinity of glycopeptides for their target. In all the VRSA strains studied, 
Tn1546 is plasmid borne (Périchon and Courvalin, 2009; Zhu et al., 2010), whether Tn1546 was transposed 
from the incoming enterococcal plasmid into a resident plasmid or, in certain instances, the enterococcal plasmid 
was maintained in the S. aureus recipient (Zhu et al., 2008). Two strains, VRSA-7 and VRSA-9, are partially 
dependent on Vancomycin for growth (Meziane-Cherif, 2010). As observed for Vancomycin-dependent 
enterococci, these isolates possess an impaired chromosomal d-Ala:d-Ala ligase (Ddl), with mutations 
responsible for 1,000- and 200-fold decreases in enzyme activity, respectively. Growth of these strains is 
enhanced in the presence of Vancomycin or Teicoplanin in the culture medium, which allows induction of the 
vanA resistance pathway. 
2.2.5.  Preventing drug access to targets 
The multidrug efflux systems contribute significantly to the increased resistance to multiple antibiotics in 
bacteria. A major challenge in developing efficacious antibiotics against drug-resistant pathogens is to identify 
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compounds that can counteract the efflux functions. The wealth of bacterial genomics information available 
suggests the presence of a variety of efflux systems in bacteria. Even a single bacterium may possess multiple 
efflux transporters of different families, with the overlapping substrate spectra. Accumulating evidence has 
indicated that the multidrug efflux system is a primary determinant of aminoglycoside resistance in 
Pseudomonas aeruginosa (Morita et al., 2012). 
 
3. STATUS OF DRUG RESISTANCE PATHOGEN IN DEVELOPING COUNTRIES 
In developing countries the self-medication of antimicrobials is a common practice, since these medications can 
often be purchased without a prescription and their sales are poorly regulated by local governments (Gassman, 
1999). In the face of these realities, drug promotion activities could lead to a greater coercive influence on 
consumers, whether they be healthy persons taking antibiotics for unjustified (e.g. fear of disease) reasons or 
patients with infectious diseases. Taken together, we suggest that the adverse downstream consequences of 
aggressive drug promotion can be more deleterious in a developing world context. This also means that the 
ethical standards and stringency by which drug promotion practices are evaluated need to be different (i.e. higher 
ethical standards and lower ethical thresholds) in the case of developing world populations that are vulnerable in 
terms of both economic access to antimicrobials and access to information and educational resources to 
objectively interpret the drug promotion material provided by drug manufacturers (WHO, 2011). 
At the turn of the century, the World Health Organization estimated that infections accounted for 45% 
of deaths in Africa and South-East Asia and that these diseases were responsible for 48% of premature deaths 
worldwide.  Bacteria cause a significant proportion of infections in Africa.  Unfortunately, in a remarkably 
short time, resistance to antibiotics has undermined the idealistic hope that bacterial infection would cease to 
be an important cause of death and disease.  Indeed, antibiotic resistance increasingly compromises the 
outcome of many infections that were, until recently, treatable and remain the most common diseases in Africa 
resistant tuberculosis (TB) infections are highly prevalent in some African countries (WHO,1998). High 
resistance rates can often be correlated to the absence of properly implemented control programs such as 
directly observed treatment, short-course schemes (Mwinga, 2001).  In a survey conducted in an area of 
Cameroon that lacks a fully functional TB control program, multi-drug resistance TB was observed in 27.6% 
of the patients with a previous history of treatment (Kuaban et al., 2000).   
TB is a pertinent case in point because it is highly prevalent in many African and other developing 
countries (Dye et al., 2002) but many other bacterial infections are severely compromised by resistance.  These 
include diseases caused by to Gram-negative enteric rods, respiratory infections, bacterial meningitis, sexually 
transmitted diseases as well as hospital acquired infections.  Due to the widespread distribution of 
Penicillinase-producing Neisseria gonorrhea, Penicillin or Ampicillin can no longer be employed in the empiric 
management of gonorrhea (Van Dyck et al., 2000; Bakare et al., 2000).  The prevalence of gonococcal 
resistance to affordable alternatives - such as Tetracyclines, Thiamphenicol and Spectinomycin - continues to 
rise and resistance to Fluoroquinolones has emerged (Van Dyck et al., 2000). 
 
4. THE GROWING CHALLENGES OF ANTIBACTERIAL DRUG RESISTANCE IN ETHIOPIA 
Similar to other developing countries, infectious diseases are a major cause of morbidity and mortality in 
Ethiopia. The Department of Disease Prevention and Control of the Ethiopian Federal Ministry of Health reports 
that the common diseases caused by bacteria include diarrheal diseases, TB, sexually transmitted infections and 
meningococcal meningitis (Goredema et al., 2006). 
In Ethiopia, there have been reports on drug resistance in M. tuberculosis, mainly from the capital city 
Addis Ababa. An earlier study conducted in Addis Ababa in 1984 on anti-TB drug resistance among new TB 
patients showed a drug resistance rate of 15% for Isoniazid), 5% for Streptomycin (SM) and 5% for both 
Isoniazid and Streptomycin. There was no Rifampicin (RIF) resistance reported and hence no multidrug-
resistant (MDR)-TB (resistant to at least isoniazid and RIF) (Lemma et al., 19 84).  
Study from south-western Ethiopia showed that 8.3% of S. aureus and 10.3% of coagulase-negative 
staphylococci were methicillin-resistant. Of the S. aureus isolates, 90.3% and 91.7% were resistant to Penicillin 
and Ampicillin, respectively (Gebre-Sealsssie, 2007). The resistance rates of S. aureus and Staphylococcus 
saprophyticus to Ampicillin were 89.0% and 92.3%, respectively. The same group of bacterial isolates showed 
resistance to Trimethoprim/ Sulfamethoxazole (SXT) at rates of 82.3% and 89.0%, whilst for Tetracycline the 
rates were 85.9% and 92.7%, respectively (Hagos and Gedif, 2009). Overall multiple drug resistance was 
93.1%, whilst 2.5% of the isolates were resistant to one antibiotic and 4.4% were sensitive to all antibiotics 
tested. In the last decade, the rate of MDR isolates from urinary tract infection patients increased from 68% to 
93.1% in Amhara Region (Tessema at al., 2007; Biadglegne and Abera, 2009). 
Gram-negative bacteria Diarrhoeal diseases impose a heavy burden on developing countries, 
accounting for 1.5 billion cases of illness a year in children under-5. The burden of diarrhoeal disease is highest 
in deprived areas where there is poor sanitation, inadequate hygiene and unsafe drinking water. In certain 
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developing countries, epidemics of diarrhoeal diseases such as cholera and dysentery affect both adults and 
children (Acar and Ro stel, 2001). Study from eastern Ethiopia reported that isolates of Salmonella and 
Shigella were resistant to six commonly used antibiotics (Ampicillin, Amoxicillin, Tetracycline, Gentamicin, 
Chloramphenicol and Norfloxacin) (Reda et al., 2001). In total, 28 Salmonella (11.5%) and 17 Shigella (6.7%) 
were isolated from 244 stool samples. The resistance rate of Salmonella isolates was 100% to Ampicillin and 
Amoxicillin, 71.4% to Tetracycline, 62.3% to Chloramphenicol and 7.1% to Norfloxacin. The resistance rate 
of Shigella isolates was 100% to Ampicillin and Amoxicillin, 70.6% to Tetracycline, 29.4% to 
Chloramphenicol and 5.9% to Norfloxacin (Reda et al., 2011). 
Salmonella clinical isolates were usually susceptible to most of the drugs tested in Addis Ababa three 
decades ago. However, >80% of the isolates displayed resistance to Ampicillin, Amoxicillin, Chloramphenicol 
and SXT in the same area by the year 2011 (Beyene et al., 2011). Moreover, resistance Escherichia coli 
isolates derived from a wide variety of clinical materials are found to be resistant to many of the commonly 
used antibiotics such as ampicillin (Gizachew et al., 2013) and most studies showed that 74% of them are 
resistant to two or more antibiotics . Reports from different clinical samples showed that >80% of Klebsiella 
spp. isolates were resistant to SXT (Alemu et al., 2012; Yismaw et al., 2012). Therefore, increasing resistance 
to antibiotics will drastically limit treatment options. In reports from 2012, wound and blood culture from 
surgically operated patients and urine cultures from pregnant women and diabetics patients showed that all 
isolates were resistant to the antibiotics that are commonly used in the country ates as high as 100% for 
ampicillin and amoxicillin have been reported in other parts of Ethiopia (Reda et al., 2011).  
 
5. THE POSSIBLE MITIGATING STRATEGIES 
5.1. Appropriate antibiotic prescribing 
Since the resistance to the first commercial antimicrobial agent (penicillin) was identified in 1948 (Barber and 
Rozwadowska, 1948), almost every known bacterial pathogen has developed resistance to one or more 
antibiotics in clinical use (Cantas et al., 2013). As antibiotic-resistant pathogens are observed almost 
concurrently with the use of new antibiotics in hospital (Levys, 1998), one can easily suppose that wherever 
antibiotics are used, antibiotic resistance will inevitably follow. Unfortunately, although antibiotic resistance has 
increased, the development of novel antimicrobial agents has dramatically declined over the past 30 years 
(Spellberg et al., 2004). Therefore, to prevent the return of the pre-antibiotic era, one must use existing 
antibiotics more judiciously. 
 
5.2. Antimicrobial stewardship programs 
Many institutions conduct Antimicrobial Stewardship Programs (ASPs) to optimize antimicrobial therapy, 
reduce treatment-related cost, improve clinical outcomes and safety, and reduce or stabilize antimicrobial 
resistance (Owens, 2008). The formal guidelines for ASPs were developed in 2007 by the Infection Diseases 
Society of America (IDSA) and the Society of Healthcare Epidemiology of America (SHEA) (Dellit et al, 2007). 
Typically, ASPs are executed by multidisciplinary antimicrobial utilization teams comprising physicians, 
pharmacists, microbiologists, epidemiologists and infectious disease specialists, with adequate experience in 
their respective fields. Many studies demonstrated that ASPs have the potential to restrict the emergence and 
spread of resistance (Drew, 2009). ASPs have demonstrated a link between antimicrobial use and the emergence 
of resistance. The following are some examples in this regard: fluoroquinolone use and MRSA (Madaras et al., 
2006); Vancomycin use and Vancomycin-resistant enterococci (Harbarth et al., 2002); Cephalosporin use and 
Cephalosporin-resistant Enterobacteriaceae (Calil, 2001); and Carbapenem use and Carbapenem-resistant 
Acinetobacter, Pseudomonas, and Enterobacteriaceae (Go et al., 1994; Rahal et al., 2002). 
 
5.3. Education 
Much of the success of ASPs depends on educating the clinicians, especially on making their everyday treatment 
decisions (Canton and Bryan, 2012). It is noteworthy that almost any clinician can prescribe antibiotics without 
any regulation or certification, whereas only specialists in oncology can prescribe and administer anti-cancer 
drugs (Owens, 2008). To optimize antimicrobial prescribing, the prescribers should have appropriate knowledge 
of general medicine, microbial virulence, immunological and genetic host factors, PK and PD properties of drugs, 
and basic knowledge of epidemiology. Prescribers of antibiotics such as physicians and pharmacists encounter 
dual, somewhat contradictory responsibilities. On the one hand, they want to provide optimal therapy for their 
patients and this responsibility tends to promote an overuse of antibiotics. On the other hand, they have a 
responsibility to future patients and to public health in sustaining the efficiency of antibiotics and minimizing 
antibiotic resistance, but this responsibility is sometimes ignored. There have been reports that about 50% of the 
antibiotic prescriptions, both in the community and in hospitals, can be considered inappropriate (inadequate 
dosing and wrong duration) (Dellit et al., 2007; Pulcini et al., 2007). As most of the antimicrobial agents are 
used in primary care (Harnden et al., 2007; Wise, 2004), education on antimicrobial prescribing in primary care 
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5.4. Hygiene and disinfection 
MDR pathogens often cause hospital-acquired infections, which require more expensive antibiotics and further 
hospitalization. Although the main source of MDR pathogens is thought to be the endogenous flora of patients, 
healthcare workers are also considered an important source (Caron and Mousa, 2010; Siegele et al., 2007). 
Therefore, appropriate hospital disinfection and personal hygiene of healthcare workers are required to prevent 
hospital-acquired infections. The Centers of Disease Control and Prevention (CDC) and the SHEA offered 
guidelines for preventing nosocomial transmission of MDR bacteria in hospitals (Muto et al., 2003; Siegel et al., 
2007). Transmission of healthcare-associated pathogens through the hands of healthcare workers is particularly 
the most common cause for spreading (Sax et al., 2009). Contamination of the hands of healthcare workers could 
result either directly from contact with patients or indirectly from touching contaminated environmental surfaces 
(Weber et al., 2010; Kramer et al., 2006). Several studies have demonstrated that an increase in hand washing 
compliance significantly decreases nosocomial infections by MRSA in intensive care units (ICUs) (Peacock et 
al., 1980; Pittet et al., 2000). WHO and the CDC presented hand hygiene guidelines in health care (Pittet et al., 
2009). 
 
6. CONTROL OF DRUG RESISTANCE IN LIVESTOCK 
To prevent the emergence and transfer of antibiotic resistance in food animals, new methods to manage 
infectious diseases in animal husbandry are required. For example, optimal use of existing vaccines can be a 
viable alternative (Potter et al., 2008). Improving hygiene (Boklund et al., 2004), using enzymes, probiotics, 
prebiotics, and acids to improve health (Callaway et al., 2008; Castanon, 2007) and utilizing bacteriocins, 
antimicrobial peptides, and bacteriophages as substitutes for antibiotics might be good methods to promote 
growth in food animals and decrease infectious diseases in them (Atterbury, 2000; Joerger, 2003). Further, it is 
worthwhile to formulate internationally acceptable standard protocols about the use of antibiotics in animal 
husbandry and about surveillance programs to monitor global emergence of MDR bacteria. 
 
7. CONCLUSION AND RECOMMENDATIONS 
The problems occurred as a result of drug résistance bacteria have an ultimate negative impact in human and 
smallholder animal production in most of the developing countries. Avoiding of using antibiotics as a growth 
promoting factors in livestock, atrict regulation on prescription of antimicrobials by health care providers and 
carrying out advanced researches to innovate novel antibacterial agents are recommended as means of alleviating 
problems related o antimicrobial reistance.  
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